Novacyt Stock

Novacyt EPS Growth

The EPS Growth of Novacyt (ALNOV.PA) as of Aug 3, 2026 is -47.50 %. In the previous year, EPS Growth was -11.11 % — a change of 327.50% (lower).

EPS Growth

-47.50 %

YoY

327.50%

Last updated:

EPS Growth of Novacyt is 2026 -47.50 % . EPS Growth of Novacyt was 2025 -11.11 % . It decreases by 327.50% lower compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

EPS Growth of Novacyt is -47.50 % in 2026.

On Eulerpool you can find the complete historical development of EPS Growth Novacyt since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Novacyt historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Growth — Novacyt

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Novacyt